Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ELANE | P08246 | 2/20 | 0.45 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074248 | 0.76 | GAA (0.61) | GAAELANEMEN1KMT2ATSHR | |
| SCHEMBL2014512 | 0.74 | PIK3CD (0.38) | GAA | |
| SCHEMBL2734368 | 0.74 | SIGMAR1 (0.54) | GAAELANECTSGSIGMAR1MC4R | |
| SCHEMBL17384429 | 0.74 | ELANE (0.47) | GAAELANECTSGPRTN3TSHR | |
| SCHEMBL3318278 | 0.74 | PIK3CD (0.51) | GAAELANECTSGPRTN3MEN1 | |
| SCHEMBL2011850 | 0.73 | NPC1 (0.42) | GAATSHRALDH1A1CYP2D6 | |
| SCHEMBL19031121 | 0.72 | GAA (0.55) | GAAELANEMEN1KMT2ATSHR | |
| SCHEMBL13484401 | 0.72 | ELANE (0.56) | GAAELANECTSGPRTN3MEN1 | |
| SCHEMBL14463068 | 0.72 | GAA (0.55) | GAAELANECTSGPRTN3MEN1 | |
| SCHEMBL23580081 | 0.71 | GAA (0.59) | GAAELANECTSGPRTN3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513069-B1 | ANTIFUNGAL COMPOUNDS | UNIV LEUVEN KATH (BE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2513069-A1 | ANTIFUNGAL COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252801-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-10-04 | — | — | US | disclosed |
| WO-2011072345-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252801-A1 | ANTIFUNGAL COMPOUNDS | ERG28, DPM1, CYP51A1 | GAA 19/4885ELANE 297/4885CTSG 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.